vimarsana.com

Latest Breaking News On - Ensem therapeutics inc - Page 1 : vimarsana.com

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

BeiGene, Ltd : BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

BeiGene, Ltd : BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Beigene gains global rights to Ensem s CDK2 inhibitor in $1 3B deal

Two-year-old Ensem Therapeutics Inc. landed a deal potentially worth $1.33 billion, if all milestones are met, with Beigene Ltd. to advance its lead IND-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor. Beigene, which has a presence in Basel, Switzerland, Beijing, and Cambridge, Mass., plans to fold the inhibitor into its breast cancer efforts, which includes its internally discovered phase I CDK4 inhibitor. Rights to the Ensem product are exclusive and global.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.